Stabilis

Dobutamine hydrochloride



Obchodný názov

Cardiforce	India
Cardiject	India, Irán, Maroko
Dobcar	Turecko
Dobucard	Argentína, India
Dobucin	Ekvádor, India
Dobucor	
Dobuject	Egypt, Mexiko, Poľsko, Saudská Arábia, Tunisko
Doburan	India, Venezuela
Dobutabag	Turecko
Dobutamex	Irán
Dobutamin	Írsko, Maďarsko, Nemecko, Nórsko, Poľsko, Rakúsko
Dobutamina	Argentína, Brazília, Čile, Ekvádor, Kolumbia, Mexiko, peru, Portugalsko, Rumunsko, Španielsko, Taliansko
Dobutamine	Belgicko, Egypt, Írsko, Kanada, Malajzia, Maroko, Poľsko, Spojené štáty Americké, Tunisko, Veľká Británia
Dobutrex	Belgicko, Brazília, Dánsko, Holandsko, Kolumbia, Luxembursko, Mexiko, Saudská Arábia, Švajčiarsko
Duvig	Argentína
Inotop	Rakúsko
Inotrex	Grécko, Portugalsko
Miozac	Taliansko
Posiject	Veľká Británia

Stabilita roztokov

		0,25 mg/ml	5°C		7			1045
		0,25 mg/ml	5°C		7			1045
	0.45	1 mg/ml	25°C		48			1058
PVC		0,25 mg/ml	5°C		7			1045
PVC		1 mg/ml	25°C	?	48			628

PVC		10 mg/ml	25°C	?	12				4141
PVC		10 mg/ml	35°C	?	12				4141
PVC		10 mg/ml	4°C	?	7				4141
PVC		0,25 mg/ml	5°C		7				1045
PVC		1 mg/ml	25°C	?	48				628
PVC		1 & 5 mg/ml	5°C		30				197
PVC		10 mg/ml	25°C	?	12				4141
PVC		10 mg/ml	35°C	?	12				4141
PVC		10 mg/ml	4°C	?	7				4141
PVC	RL	1 mg/ml	25°C	?	48				628
PVC	0.45	1 mg/ml	25°C	?	48				628
PVC	0.45	1 mg/ml	25°C		48				1058
PVC	Δ® P1 ◆1.5	0,0025 mg/ml	26°C	?	4				2371
PVC	Δ® P1 ◆1.5	0,0025 mg/ml	4°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,005 mg/ml	26°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,005 mg/ml	37°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,005 mg/ml	4°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,0075 mg/ml	26°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,0075 mg/ml	37°C	?	24				2371
PVC	Δ® P1 ◆1.5	0,0075 mg/ml	4°C	?	24				2371
PE		0,5 mg/ml	22°C		24				1067
PE		0,5 mg/ml	4°C		24				1067
PE		0,5 mg/ml	22°C		24				1067
PE		0,5 mg/ml	4°C		24				1067
PP		10 mg/ml	-25 >> -15°C		90				4584
PP		10 mg/ml	2-8°C		365				4584
PP		10 mg/ml	23-27°C		30				4584
PP		10 mg/ml	-25 >> -15°C		21				4584
PP		10 mg/ml	2-8°C		365				4584
PP		10 mg/ml	20°C		35				3293
PP		10 mg/ml	4°C		42				3293
PP		5 mg/ml	23-25°C	±	48				206
PP		5 mg/ml	25°C		24				196

		5 mg/ml	4°C		48			206
		10 mg/ml	-25 >> -15°C		365			4584
		10 mg/ml	2-8°C		365			4584
		10 mg/ml	23-27°C		365			4584
		10 mg/ml	-25 >> -15°C		365			4584
		10 mg/ml	2-8°C		365			4584
		10 mg/ml	23-27°C		365			4584
?		4 mg/ml	23°C		30			1753
?		4 mg/ml	5°C		30			1753

Stabilita v zmesiach

		0,25 & 5 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4	1603
		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7	1045
		2 mg/ml	?	?	Nitroprusside sodium : 0,2 mg/ml Nitroglycerin : 0,2 mg/ml	24	1109
		2,5 mg/ml	20°C-25°C		Labetalol hydrochloride : 1 mg/ml	4	199
		0,25 & 5 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4	1603
		5 mg/ml	22°C		Nitroprusside sodium : 1,2 mg/ml	24	3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24	3381
		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24	3381
		4 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4	813
		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7	1045
PVC		1 mg/ml	23°C		Zidovudine : 2 mg/ml	24	1878
PVC		1 mg/ml	4°C	?	Zidovudine : 2 mg/ml	24	1878
PVC		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7	1045
PVC		0,25 & 1 mg/ml	?	?	Ranitidine hydrochloride : 0,05 & 2 mg/ml	48	210
PVC		2 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24	187
PVC		1 mg/ml	23°C		Zidovudine : 2 mg/ml	24	1878
PVC		1 mg/ml	4°C	?	Zidovudine : 2 mg/ml	24	1878
PVC		0,25 mg/ml	5°C		Verapamil hydrochloride : 0,16 mg/ml	7	1045
PVC		0,25 & 1 mg/ml	?	?	Ranitidine hydrochloride : 0,05 & 2 mg/ml	48	210

PE		5 mg/ml	22°C		Nitroprusside sodium : 1,2 mg/ml	24	3381
PE		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml	24	3381
PE		5 mg/ml	22°C		Norepinephrine bitartrate : 0,06 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24	3381
PP		8 mg/ml	22-25°C		Dopamine hydrochloride : 8 mg/ml	24	1506
PP		8 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24	1506
PP		8 mg/ml	22-25°C		Midazolam hydrochloride : 4 mg/ml	24	1506
PP		8 mg/ml	22-25°C		Dopamine hydrochloride : 8 mg/ml	24	1506
PP		8 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24	1506

Faktory ovplyvňujúce stabilitu

					3293
					197
	NaH CO3				1041 1058 3606
	pH >7				3606
	pH > 6				197

Kompatibility

1		Dobutamine hydrochloride : 1 mg/ml Aciclovir sodium : 5 mg/ml		336
?		Dobutamine hydrochloride Aciclovir sodium		3595
		Dobutamine hydrochloride : 10 mg/ml Alprostadil : 20 µg/ml		4651
		Dobutamine hydrochloride : 10 mg/ml Alprostadil : 20 µg/ml		4491
		Dobutamine hydrochloride : 3 mg/ml Alprostadil : 15 µg/ml		3201
		Dobutamine hydrochloride : 2 mg/ml Alteplase : 1 mg/ml		92
		Dobutamine hydrochloride : 5 mg/ml Alteplase : 0.5 mg/ml		240
		Dobutamine hydrochloride : 4 mg/ml Amifostine : 10 mg/ml		3
4		Dobutamine hydrochloride : 1 mg/ml Aminophylline : 1 mg/ml		1058

		Dobutamine hydrochloride : 2 mg/ml Aminophylline : 5 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Aminophylline : 1 mg/ml		1058
		Dobutamine hydrochloride : 10 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
		Dobutamine hydrochloride : 10 mg/ml Amiodarone hydrochloride : 12,5 mg/ml		4119
		Dobutamine hydrochloride : 2 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
		Dobutamine hydrochloride : 10 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Dobutamine hydrochloride : 10 mg/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Dobutamine hydrochloride : 2 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
		Dobutamine hydrochloride : 2 mg/ml Amiodarone hydrochloride : 5 mg/ml		1041
		Dobutamine hydrochloride : 12,5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Dobutamine hydrochloride : 4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Dobutamine hydrochloride : 4 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Dobutamine hydrochloride : 12,5 mg/ml Argatroban : 1 mg/ml		1964
		Dobutamine hydrochloride : 1 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Dobutamine hydrochloride : 0,17 mg/ml Atropine sulfate : 0,017 mg/ml		1221
		Dobutamine hydrochloride : 2 mg/ml Atropine sulfate : 0.1 mg/ml		1041
		Dobutamine hydrochloride : 4 mg/ml Aztreonam : 40 mg/ml		99
		Dobutamine hydrochloride : 4 mg/ml Bivalirudin		3539
		Dobutamine hydrochloride : 4 mg/ml Bivalirudin : 5 mg/ml		1713
		Dobutamine hydrochloride : 12,5 mg/ml Bivalirudin : 5 mg/ml		1944
		Dobutamine hydrochloride : 12.5 mg/ml Bivalirudin		3539
		Dobutamine hydrochloride : 12,5 mg/ml Bivalirudin : 5 mg/ml		1944
		Dobutamine hydrochloride : 1 mg/ml Bretylium tosilate : 2 mg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Bretylium tosilate : 8 & 50 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Bretylium tosilate : 2 mg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Bumetanide : 0.25 mg/ml		1041

		Dobutamine hydrochloride : 7.2 mg/ml Caffeine : 10 mg/ml	◆	4837
		Dobutamine hydrochloride : 12.5 mg/ml Caffeine : 10 mg/ml	∅	3964
		Dobutamine hydrochloride : 7.2 mg/ml Caffeine : 10 mg/ml	▲	4837
		Dobutamine hydrochloride : 7,2 mg/ml Caffeine citrate : 20 mg/ml	▲	4837
		Dobutamine hydrochloride : 7,2 mg/ml Caffeine citrate : 20 mg/ml	◆	4837
		Dobutamine hydrochloride : 0,18 mg/ml Calcium chloride : 9,1 mg/ml	▲	1221
		Dobutamine hydrochloride : 1 mg/ml Calcium chloride : 2 mg/ml	▲	1058
		Dobutamine hydrochloride : 2 mg/ml Calcium chloride : 100 mg/ml	◆	1041
		Dobutamine hydrochloride : 1 mg/ml Calcium chloride : 2 mg/ml	◆	1058
		Dobutamine hydrochloride : 1 mg/ml Calcium gluconate : 2 mg/ml	◆	1058
		Dobutamine hydrochloride : 1 mg/ml Calcium gluconate : 2 mg/ml	▲	1058
		Dobutamine hydrochloride : 2 mg/ml Calcium gluconate : 100 mg/ml	◆	1041
		Dobutamine hydrochloride Calcium gluconate		3644
		Dobutamine hydrochloride Calcium gluconate		4964
		Dobutamine hydrochloride : 1 mg/ml Caspofungin acetate : 0.5 mg/ml	▲	2233
		Dobutamine hydrochloride : 4 mg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Dobutamine hydrochloride : 1 mg/ml Cefepime dihydrochloride : 125 mg/ml	💧	2141
		Dobutamine hydrochloride : 4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	◆	4528
		Dobutamine hydrochloride : 4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
		Dobutamine hydrochloride : 4.2 mg/ml Cefmetazole sodium : 100 mg/ml	💧	93
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	◆	3249
		Dobutamine hydrochloride : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	▲	3249
		Dobutamine hydrochloride : 1 mg/ml Ceftazidime : 125 mg/ml	💧	2141
		Dobutamine hydrochloride : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	▲	2269
		Dobutamine hydrochloride Ceftobiprole medocaril sodium		4650

		Dobutamine hydrochloride : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Dobutamine hydrochloride : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Dobutamine hydrochloride : 4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dobutamine hydrochloride : 4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dobutamine hydrochloride : 0.25 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dobutamine hydrochloride : 0.25 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dobutamine hydrochloride : 2 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Dobutamine hydrochloride : 4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Dobutamine hydrochloride : 4 mg/ml Cladribine : 0.015 mg/ml		1496
		Dobutamine hydrochloride : 4 mg/ml Cladribine : 0.5 mg/ml		1496
		Dobutamine hydrochloride : 2 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Dobutamine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Dobutamine hydrochloride : 8 mg/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Dobutamine hydrochloride : 12,5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
4		Dobutamine hydrochloride Conivaptan		3715
		Dobutamine hydrochloride Dexmedetomidine		5042
		Dobutamine hydrochloride : 4 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Dobutamine hydrochloride : 2 mg/ml Diazepam : 5 mg/ml		1041
24		Dobutamine hydrochloride : 1 mg/ml Digoxin : 4 µg/ml		1058
24		Dobutamine hydrochloride : 1 mg/ml Digoxin : 4 µg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
		Dobutamine hydrochloride : 1 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Dobutamine hydrochloride : 4 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride Dimenhydrinate		2087
		Dobutamine hydrochloride : 4 mg/ml Docetaxel : 0.9 mg/ml		1754
		Dobutamine hydrochloride : 2 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1041

		Dobutamine hydrochloride : 0,17 mg/ml Dopamine hydrochloride : 5,52 mg/ml		1221
		Dobutamine hydrochloride : 10 mg/ml Dopamine hydrochloride : 20 mg/ml		3823
		Dobutamine hydrochloride : 1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1058
		Dobutamine hydrochloride : 4 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Dobutamine hydrochloride : 8 mg/ml Dopamine hydrochloride : 8 mg/ml		1506
		Dobutamine hydrochloride : 1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		1058
		Dobutamine hydrochloride : 8 mg/ml Dopamine hydrochloride : 8 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Doripenem : 5 mg/ml		2262
		Dobutamine hydrochloride : 4 mg/ml Doripenem : 5 mg/ml		2262
		Dobutamine hydrochloride : 2 mg/ml Epinephrine hydrochloride : 0.1 µg/ml		1041
		Dobutamine hydrochloride Eptifibatide		3934
		Dobutamine hydrochloride : 4,1 mg/ml Eravacycline : 0,6 mg/ml		4434
		Dobutamine hydrochloride : 8 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Dobutamine hydrochloride : 1 mg/ml Famotidine : 0.2 mg/ml		398
		Dobutamine hydrochloride : 5 mg/ml		316
		Dobutamine hydrochloride : 4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Dobutamine hydrochloride : 1 mg/ml Enalaprilate : 0.0125 mg/ml		1703
		Dobutamine hydrochloride : 0,91 mg/ml Enalaprilate : 0,011 mg/ml		963
		Dobutamine hydrochloride : 1 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Dobutamine hydrochloride : 4 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Dobutamine hydrochloride : 8 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Dobutamine hydrochloride : 40 mg/ml Famotidine : 2 mg/ml		215
		Dobutamine hydrochloride : 4 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Dobutamine hydrochloride : 2 mg/ml Fentanyl citrate : 50 µg/ml		63
		Dobutamine hydrochloride : 4 mg/ml Fentanyl citrate : 50 µg/ml		314
		Dobutamine hydrochloride : 50 mg/ml		939

		Dobutamine hydrochloride : 4 mg/ml		301
6		Dobutamine hydrochloride : 2 mg/ml	NaH CO3	1041
15'		Dobutamine hydrochloride : 1 mg/ml	NaH CO3	1058
?		Dobutamine hydrochloride	NaH CO3	3606
		Dobutamine hydrochloride : 2 mg/ml	Normo Sol®	4655
		Dobutamine hydrochloride : 2 mg/ml	Pl 148	4835
		Dobutamine hydrochloride : 8 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Dobutamine hydrochloride : 8 mg/ml Fentanyl citrate : 30 µg/ml		1506
		Dobutamine hydrochloride : 0.5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Dobutamine hydrochloride : 2 mg/ml Fluconazole : 2 mg/ml		255
		Dobutamine hydrochloride : 2 mg/ml Flumazenil : 0,02 mg/ml		187
		Dobutamine hydrochloride : 12.5 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Dobutamine hydrochloride : 4.1 mg/ml Fosfomycin : 30 mg/ml		4055
		Dobutamine hydrochloride : 4.1 mg/ml Fosfomycin : 30 mg/ml		4055
		Dobutamine hydrochloride : 0.5 mg/ml Furosemide : 1 mg/ml		1232
		Dobutamine hydrochloride : 2 mg/ml Furosemide : 10 mg/ml		1041
		Dobutamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
1		Dobutamine hydrochloride : 1 mg/ml Furosemide : 1 mg/ml		1058
1		Dobutamine hydrochloride : 1 mg/ml Furosemide : 1 mg/ml		1058
		Dobutamine hydrochloride : 8 mg/ml Furosemide : 2 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Furosemide : 10 mg/ml		314
		Dobutamine hydrochloride : 7,2 mg/ml		4924
		Dobutamine hydrochloride : 4 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
		Dobutamine hydrochloride		3606
		Dobutamine hydrochloride : 12,5 mg/ml	RL	4603
		Dobutamine hydrochloride : 5 mg/ml Furosemide : 10 mg/ml	∅	3210
		Dobutamine hydrochloride : 4 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dobutamine hydrochloride : 1 mg/ml Heparin sodium : 50 UI/ml	∅	317

		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		1041
		Dobutamine hydrochloride : 4 mg/ml		1415
		Dobutamine hydrochloride : 4 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Dobutamine hydrochloride : 1 mg/ml Heparin sodium : 40 UI/ml		1058
6		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 10000 UI/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		1352
		Dobutamine hydrochloride : 4 mg/ml Heparin sodium : 100 UI/ml		295
		Dobutamine hydrochloride : 4 mg/ml Heparin sodium : 100 UI/ml		314
		Dobutamine hydrochloride : 1 mg/ml Heparin sodium : 40 UI/ml		1058
		Dobutamine hydrochloride Heparin sodium		3540
		Dobutamine hydrochloride : 4 mg/ml Hetastarch : 60 mg/ml		1721
		Dobutamine hydrochloride : 0,2 mg/ml Hydralazine hydrochloride : 0,2 mg/ml		1221
		Dobutamine hydrochloride : 4 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride Hydroxocobalamin		3932
		Dobutamine hydrochloride : 1 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Dobutamine hydrochloride : 4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Dobutamine hydrochloride : 4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Dobutamine hydrochloride : 1.2 mg/ml Indomethacin sodium trihydrate : 1 mg/ml		467
		Dobutamine hydrochloride : 2 mg/ml Insulin : 100 UI/ml		1041
		Dobutamine hydrochloride : 8 mg/ml Insulin : 1 UI/ml		1506
24		Dobutamine hydrochloride : 1 mg/ml Insulin : 1 UI/ml		1058
24		Dobutamine hydrochloride : 1 mg/ml Insulin : 1 UI/ml		1058
		Dobutamine hydrochloride : 8 mg/ml Insulin : 1 UI/ml		1506
		Dobutamine hydrochloride : 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Dobutamine hydrochloride : 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Dobutamine hydrochloride : 4.1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829

		Dobutamine hydrochloride : 4.1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Dobutamine hydrochloride : 2 mg/ml Isoprenaline hydrochloride : 0.004 mg/ml		1041
		Dobutamine hydrochloride : 12.5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Dobutamine hydrochloride : 2.5 mg/ml Labetalol hydrochloride : 1 mg/ml		199
		Dobutamine hydrochloride : 4 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Dobutamine hydrochloride : 4 mg/ml Labetalol hydrochloride : 5 mg/ml		295
		Dobutamine hydrochloride : 4 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Dobutamine hydrochloride : 2 mg/ml Levetiracetam : 100 mg/ml		4108
		Dobutamine hydrochloride : 12,5 mg/ml Levofloxacine : 5 mg/ml		1072
		Dobutamine hydrochloride : 2 mg/ml Lidocaine hydrochloride : 8 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Lidocaine hydrochloride : 4 mg/ml		1058
		Dobutamine hydrochloride : 1 mg/ml Lidocaine hydrochloride : 4 mg/ml		1058
		Dobutamine hydrochloride : 4 mg/ml Linezolid : 2 mg/ml	∅	1925
		Dobutamine hydrochloride : 4 mg/ml Lorazepam : 0.5 mg/ml		314
		Dobutamine hydrochloride : 0,17 mg/ml Magnesium sulfate : 83,3 mg/ml		1221
		Dobutamine hydrochloride : 1 mg/ml Magnesium sulfate : 2 mg/ml		1058
		Dobutamine hydrochloride : 1 mg/ml Magnesium sulfate : 2 mg/ml		1058
		Dobutamine hydrochloride : 12.5 mg/ml Meropenem : 50 mg/ml		4319
		Dobutamine hydrochloride : 1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Dobutamine hydrochloride : 2 mg/ml Metaraminol : 0.2 mg/ml		1041
		Dobutamine hydrochloride : 8 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Dobutamine hydrochloride : 8 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Micafungin : 1.5 mg/ml		2108
		Dobutamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Dobutamine hydrochloride : 8 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
		Dobutamine hydrochloride : 4 mg/ml Midazolam hydrochloride : 1 mg/ml		295

		Dobutamine hydrochloride : 2 mg/ml Midazolam hydrochloride : 1 mg/ml	◆	176
		Dobutamine hydrochloride : 4 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Dobutamine hydrochloride : 16 mg/ml Milrinone lactate : 0.8 mg/ml	◆	813
		Dobutamine hydrochloride : 4 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Dobutamine hydrochloride : 8 mg/ml Morphine hydrochloride : 1 mg/ml	▲	1506
		Dobutamine hydrochloride : 8 mg/ml Morphine hydrochloride : 1 mg/ml	◆	1506
		Dobutamine hydrochloride : 4 mg/ml Morphine sulfate : 2 mg/ml		314
		Dobutamine hydrochloride : 2 mg/ml Morphine sulfate : 10 mg/ml	◆	1041
		Dobutamine hydrochloride : 12.5 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Dobutamine hydrochloride : 12.5 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Dobutamine hydrochloride : 4 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride : 1 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	▲	1490
		Dobutamine hydrochloride : 1 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	◆	1490
		Dobutamine hydrochloride : 2 mg/ml Nitroglycerin : 0.24 mg/ml	◆	1041
		Dobutamine hydrochloride : 4 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Dobutamine hydrochloride : 5 mg/ml Nitroprusside sodium : 1.2 mg/ml	◆	2879
		Dobutamine hydrochloride : 5 mg/ml Nitroprusside sodium : 1,2 mg/ml	◆	3177
		Dobutamine hydrochloride : 8 mg/ml Norepinephrine bitartrate : 0.32 mg/ml	◆	1506
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0.06 mg/ml	◆	3381
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0.06 mg/ml	◆	2879
		Dobutamine hydrochloride : 4 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Dobutamine hydrochloride : 5 mg/ml Norepinephrine bitartrate : 0,06 mg/ml	◆	3177
		Dobutamine hydrochloride : 10 mg/ml Norepinephrine bitartrate : 0.96 mg/ml	◆	3823
		Dobutamine hydrochloride : 8 mg/ml Norepinephrine bitartrate : 0.32 mg/ml	▲	1506
		Dobutamine hydrochloride : 2 mg/ml Norepinephrine bitartrate : 0.064 mg/ml	◆	1041
		Dobutamine hydrochloride : 4 mg/ml Oritavancin : 0.8 >>2 mg/ml	◆	3152

		Dobutamine hydrochloride : 4 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Dobutamine hydrochloride : 1 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Dobutamine hydrochloride : < 4 mg/ml Pantoprazole sodium : < 0.05 mg/ml		1902
		Dobutamine hydrochloride Pantoprazole sodium		2090
		Dobutamine hydrochloride : 1 >> 4 mg/ml Pantoprazole sodium : 0,16 >> 0,8 mg/ml		1902
		Dobutamine hydrochloride : 12.5 mg/ml Paracetamol : 10 mg/ml		4742
		Dobutamine hydrochloride : 4 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Dobutamine hydrochloride : 2,4 & 7,2 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Dobutamine hydrochloride : 1.2 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Dobutamine hydrochloride : 2,4 & 7,2 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Dobutamine hydrochloride : 2 mg/ml Pethidine hydrochloride : 100 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Dobutamine hydrochloride Phentolamine mesylate		5050
		Dobutamine hydrochloride : 2 mg/ml Phentolamine mesylate : 0.04 mg/ml		1041
		Dobutamine hydrochloride : 2 mg/ml Phenylephrine hydrochloride : 0.04 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Phenytoin sodium : 1 mg/ml		1058
		Dobutamine hydrochloride : 2 mg/ml Phenytoin sodium : 50 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Phenytoin sodium : 1 mg/ml		1058
		Dobutamine hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Dobutamine hydrochloride : 4.1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Dobutamine hydrochloride Posaconazole		4380
		Dobutamine hydrochloride : 2 mg/ml Potassium chloride : 40 mEq/l		1041
		Dobutamine hydrochloride : 1 mg/ml Potassium chloride : 160 mEq/l		1058
		Dobutamine hydrochloride : 1 mg/ml Potassium chloride : 160 mEq/l		1058
		Dobutamine hydrochloride : 0.19 mg/ml Potassium phosphate		1221
		Dobutamine hydrochloride : 2 mg/ml Procainamide hydrochloride : 8 & 100 mg/ml		1041

		Dobutamine hydrochloride : 1 mg/ml Procainamide hydrochloride : 1 mg/ml		1058
		Dobutamine hydrochloride : 1 mg/ml Procainamide hydrochloride : 1 mg/ml		1058
12		Dobutamine hydrochloride : 1 mg/ml Propofol		660
		Dobutamine hydrochloride : 4 mg/ml Propofol : 10 mg/ml	∅	300
		Dobutamine hydrochloride : 2 mg/ml Propranolol hydrochloride : 1 mg/ml		1041
		Dobutamine hydrochloride : 1 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396
		Dobutamine hydrochloride : 4 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Dobutamine hydrochloride : 0.25 & 1 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Dobutamine hydrochloride : 4 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Dobutamine hydrochloride : 12.5 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Dobutamine hydrochloride : 7.2 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
6		Dobutamine hydrochloride : 2 mg/ml Sodium bicarbonate : 84 mg/ml		1041
15'		Dobutamine hydrochloride : 1 mg/ml Sodium bicarbonate : 50 mg/ml		1058
?		Dobutamine hydrochloride Sodium bicarbonate		3606
1		Dobutamine hydrochloride : 2 mg/ml Streptokinase : 30000 UI/ml		92
		Dobutamine hydrochloride : 12.5 mg/ml Sugammadex : 100 mg/ml	∅	3372
		Dobutamine hydrochloride : 4,1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Dobutamine hydrochloride : 1 mg/ml Tacrolimus : 1000 µg/ml		479
		Dobutamine hydrochloride : 4.1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Dobutamine hydrochloride : 4 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Dobutamine hydrochloride : 4 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Dobutamine hydrochloride : 4 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Dobutamine hydrochloride : 1 mg/ml Temocilline : 83.33 mg/ml		2231

		Dobutamine hydrochloride : 1 mg/ml Theophylline : 4 mg/ml	∅	317
		Dobutamine hydrochloride : 12.5 mg/ml Thiopental sodium : 25 mg/ml	▲	3767
		Dobutamine hydrochloride : 4 mg/ml Thiopental sodium : 25 mg/ml		314
		Dobutamine hydrochloride : 4 mg/ml Thiotepa : 1 mg/ml	◆	249
		Dobutamine hydrochloride Tigecycline	▲	3332
		Dobutamine hydrochloride : 0,25 & 5 mg/ml Tirofiban : 50 µg/ml	◆	1603
		Dobutamine hydrochloride Tirofiban		1512
		Dobutamine hydrochloride : 0,25 & 5 mg/ml Tirofiban : 50 µg/ml	▲	1603
		Dobutamine hydrochloride : 2 mg/ml Valproic acid : 10 mg/ml	◆	3942
		Dobutamine hydrochloride : 1 mg/ml Vancomycin hydrochloride : 10 mg/ml	◆	3385
		Dobutamine hydrochloride : 4.2 mg/ml Vasopressin : 2 & 4 UI/ml	▲	1801
		Dobutamine hydrochloride : 4 mg/ml Vecuronium bromide : 1 mg/ml		314
		Dobutamine hydrochloride : 1 mg/ml Vecuronium bromide : 0.1 mg/ml	◆	402
		Dobutamine hydrochloride : 0.25 mg/ml Verapamil hydrochloride : 0.16 mg/ml	◆	1045
24		Dobutamine hydrochloride : 0.5 mg/ml Verapamil hydrochloride : 0.08 mg/ml	◆	1057
		Dobutamine hydrochloride : 2 mg/ml Verapamil hydrochloride : 2.5 mg/ml	◆	1041
		Dobutamine hydrochloride : 1 mg/ml Zidovudine : 2 mg/ml	▲	1878
		Dobutamine hydrochloride	▲	3606
24		Dobutamine hydrochloride : 0.5 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲	1057
		Dobutamine hydrochloride : 0.25 mg/ml Verapamil hydrochloride : 0.16 mg/ml	▲	1045
		Dobutamine hydrochloride : 1 mg/ml Warfarin sodium : 2 mg/ml	◆	315
		Dobutamine hydrochloride : 5 mg/ml Zidovudine : 4 mg/ml	◆	337
		Dobutamine hydrochloride : 2 mg/ml	Pl 148 ◆	4835

spôsob podania

Odkazy na literatúru

	Typ	Publikácia
3	Časopis	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Časopis	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Časopis	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
63	Časopis	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Časopis	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Časopis	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
92	Časopis	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Časopis	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Časopis	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
176	Časopis	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
187	Časopis	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
196	Časopis	Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207.

197	Časopis	Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340.
198	Časopis	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Časopis	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
206	Časopis	Sautou-Miranda V, Gremeau I, Chamard I, Cassagnes J, Chopineau J. Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. Am J Health-Syst Pharm 1996 ; 53: 186.
210	Časopis	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Časopis	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Časopis	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	Časopis	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
249	Časopis	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
255	Časopis	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
266	Časopis	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
285	Časopis	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Časopis	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
295	Časopis	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Časopis	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Časopis	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Časopis	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Časopis	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Časopis	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
336	Časopis	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Časopis	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
396	Časopis	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
398	Časopis	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Časopis	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
403	Časopis	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
467	Časopis	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Časopis	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
524	Časopis	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
628	Časopis	Kirschenbaum HL, Aronoff W, Perentesis GP, Piltz GW, Goldberg RJ, Cutie AJ. Stability of dobutamine hydrochloride in selected large-volume parenterals. Am J Hosp Pharm 1982 ; 39: 1923-1925.

660	Časopis	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Časopis	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
921	Časopis	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Časopis	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Časopis	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1036	Časopis	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Časopis	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1045	Časopis	Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. Am J Hosp Pharm 1984 ; 41: 686-689.
1057	Časopis	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Časopis	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1067	Časopis	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1072	Časopis	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1109	Časopis	Horrow JC, Digregorio J, Barbieri EJ, Rupp E. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med 1990 ; 18: 858-861.
1221	Časopis	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1232	Časopis	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.

1352	Časopis	Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984 ; 41: 2588-2589.
1410	Časopis	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Časopis	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Časopis	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	Časopis	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Časopis	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratórium	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1603	Časopis	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1625	Časopis	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Časopis	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1703	Časopis	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Časopis	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Časopis	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Časopis	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1753	Časopis	Webster AA, English BA, McGuire JM, Riggs RM, Lander V, Buckle T. Stability of dobutamine hydrochloride 4 mg/ml in 5% dextrose injection at 5 and 23°C. Int J Pharm Compound 1999 ; 3: 412-414.

1754	Časopis	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	Časopis	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Časopis	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1878	Časopis	Musami P, Stewart JT, Will Taylor E. Stability of zidovudine and dobutamine hydrochloride injections in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23±2°C) and 4°C in 50 ml polyvinyl chloride bags up to 24 hours. Int J Pharm Compound 2004 ; 8, 1: 73-76.
1902	Časopis	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Časopis	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Časopis	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1953	Časopis	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964	Časopis	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1982	Časopis	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Časopis	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Časopis	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Časopis	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Časopis	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Časopis	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Časopis	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.

2231	Časopis	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Časopis	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Časopis	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Časopis	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2371	Časopis	Gora ML, Seth S, Visconti JA, Shields B, Bay W. Stability of dobutamine hydrochloride in peritoneal dialysis solutions Am J Hosp Pharm 1991 ; 48: 1234 - 1237.
2879	Poster	Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008
3012	Časopis	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Časopis	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177	Poster	Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010
3201	Časopis	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3210	Časopis	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3216	Časopis	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Časopis	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Časopis	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3293	Časopis	Patel N, Taki M, Tunstell P, Forsey P, Forbes B. Stability of dobutamine 500 mg in 50 ml syringes prepared using a Central Intravenous Additive Service EJHP 2012 ; 19: 52-56.

3332	Laboratórium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Časopis	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3381	Časopis	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3385	Časopis	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Časopis	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Laboratórium	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratórium	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3595	Laboratórium	Aciclovir - Summary of Product Characteristics Hospira 2009
3606	Laboratórium	Dobutamine - Summary of Product Characteristics Wokhardt 2013
3644	Laboratórium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3715	Časopis	Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535
3766	Časopis	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Časopis	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Časopis	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Časopis	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratórium	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015

3934	Laboratórium	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3942	Časopis	Frank M.I, Boddu S.H.S, . Mauro V.F,. Churchwell M.D. Physical compatibility of valproate sodium injection with dobutamine and dopamine. Am J Health-Syst Pharm 2017 ; 74, 5: 280-281.
3964	Časopis	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4108	Časopis	Cruz K, Chrchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4141	Časopis	Al Madfai F, Valah B, Zaidi S.T.R, Wanandy T, Ming M.C, Peterson G.M, Patel R.P. Stability of dobutamine in continuous ambulatory delivery devices. J Clin Pharm Ther 2018 : 530-535.
4145	Časopis	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Časopis	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratórium	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4419	Časopis	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	Časopis	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Časopis	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4528	Časopis	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Časopis	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4543	Časopis	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.

4584	Časopis	Gilliot S, Henry H, Carta N, Genay S, Barthélémy C, Décaudin B, Odou P. Long-term stability of 10 mg/mL dobutamine injectable solutions in 5% dextrose and normal saline solution stored in polypropylene syringes and cyclic-oleofin- copolymer vials. EJHP 2023 ; 30, 3: 153-159.
4603	Časopis	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratórium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Časopis	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Časopis	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Časopis	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4835	Časopis	Hammond S, Wignell A, Cooling P, Barrett D.A, Davies P. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental 2020 8:25.
4837	Časopis	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	Časopis	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4924	Časopis	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:
4964	Laboratórium	GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit. B BRAUN MELSUNGEN AG 2019
5042	Laboratórium	Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. Orion Corporation 2016
5050	Laboratórium	Phentolamine - Drugs.com monograph Drugs.com 2025

slovník

	kardiotonikum		Injekcia
	Obchodný názov		Stabilita roztokov
	obal		Zlúčenina
	koncentrácia		teplota
	uchovávanie		Trvanie stability
	Biologicky podobný liek		konfliktné údaje
	odkazy na lieteratúru		Sklo
	0,9% chlorid sodný		Chránené pred svetlom
	dní		5% glukóza
	0,45% chlorid sodný (a) 5% glukóza		Za svetla
	hodín	PVC	polyvinylchlorid (PVC)
?	nešpecifikované	RL	Ringerov laktátový roztok
Δ® P1 ◆1.5	Dianéal® PD1 1.5% glukóza (Baxter)	PE	polyetylén
	Injekčná striekačka polypropylén		Za svetla alebo chránené pred svetlom
	AT-Closed vial®	?	nešpecifikované
	Stabilita v zmesiach		rozpúšťadlo
	Zlúčenina	PP	polypropylén
	Faktory ovplyvňujúce stabilitu		indukuje
	degradácia		zlepšená stabilita
NaH CO3	NaHCO3		Kompatibility
1	Zmena farby po 1 hodine		nezlučiteľný
	Nešpecifikovaná nekompatibilita		kompatibilný
	Okamžité zrážanie		voda na injekciu
4	Zákal za 4 hodiny	12	Zrážky po 12 hodinách
	Okamžitá zákal	24	Zmena farby po 24 hodinách
	Zmena farby	Ø	Žiadny
24	Zákal za 24 hodiny	24	Zrážky po 24 hodinách
	0,9% chlorid sodný + antibakteriálna látka	4	Zmena farby po 4 hodinách
	parenterálna výživa (binárna zmes)	6	Zrážky po 6 hodinách
15'	Zrážky po 15 hodinách	Normo Sol®	Normosol®

Pl 148	Plasmalyte 148 (Baxter)
	Parenterálna výživa (lipidy)
	Zrážky po 4 hodinách
	Chemická nestabilita
	Zrážky po 1 hodine
Pl 148	Plasmalyte 148 dextrose 5% (Baxter)
	kontinuálna infúzia
	slovník

	Zákal za jednu hodinu
	Zmena farby po 6 hodinách
	Špeciálne rozpúšťadlá
	Zrážky po 8 hodinách
	Nestabilita emulzie po 12 hodinách
	spôsob podania
	Odkazy na literatúru